Cell-Free DNA in the Management of Colorectal Cancer.
Fiche publication
Date publication
janvier 2020
Journal
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Lien Pubmed
Résumé
Colorectal cancer is one of the leading cause of death by cancer worldwide in both men and women. Liquid biopsy belongs nowadays to the landscape of cancer management biological tools. In this chapter, we will describe and discuss the actual, potential and future applications of cfDNA analysis in plasma of patients with colorectal cancer in early or metastatic stage. During the last decade, the development of molecular biology assays like digital PCR or next-generation sequencing made the analysis of cfDNA in plasma possible with an excellent sensitivity and applications like early detection, diagnosis, prognosis, response to treatment, monitoring of an emerging resistance, mapping of the disease molecular landscape or evaluation of the residual disease are now feasible. cfDNA detection has several promising applications in the management of patients with colorectal cancer, but prospective randomised clinical trials are still lacking to make liquid biopsy ready for prime-time.
Mots clés
Colorectal cancer, Diagnosis, Early detection, Metastatic colorectal cancer, Monitoring, Prognosis, cfDNA
Référence
Recent Results Cancer Res.. 2020 ;215:253-261